Haemophilus ducreyi bacterium is responsible for the sexually transmitted infection known as Chancroid. Due to our expertise in exploring chancroid vaccine and therapy development, our company is positioned to deliver onestop solutions' to all global pharmaceutical companies.
Overview of Chancroid
Chancroid, or soft chancre, is painless necrotic genital ulcers, which is worse because it is highly infectious sexually transmitted disease. Chancroid is primarily caused by the gram negative bacterium Haemophilus ducreyi, the primary area that this pathogen invades is the genitals. This pathogen targets the mucosal tissues, causing the tissue to bleed and eventually form sores with swollen lymph nodes in the affected people.
Fig. 1 Example of gram stain analysis in chancroid. (Putri P.T.A.D., et al., 2021)
Vaccine Development for Chancroid
For infectious diseases, vaccination has remained the most effective way of infection prevention and control. The target of the developing Chancroid Vaccine should be the ever Haemophilus Ducreyi so that the immune system would be prevented from acquiring the Chancroid disease.
In reverse vaccinology, one starts with genomic and proteomic interrogation of the pathogen in an effort to identify possible immunogenic components. Conservation of sequences and use of bioinformatics tools in a variety of algorithms can lead scientists to seek out greatly immunogenic epitopes or antigens.
Therapeutics Development for Chancroid
Currently, antibiotic therapy is the mainstay for treating chancroid. The choice of antibiotic depends on the susceptibility patterns of the local strains of H. ducreyi. Recommended antibiotics include ceftriaxone, azithromycin, and erythromycin. However, the emergence of antibiotic resistance poses a significant challenge in the effective management of chancroid. Therefore, our focus extends beyond conventional antibiotics, as we explore innovative approaches such as targeted therapies and immunomodulatory agents to enhance outcomes. Please click on the link below to learn more about our one-stop solutions.
Our Services
Having a strong cadre of resourceful scientists and researchers, we take great delight in advancing the frontiers of science and technology in the fight against chancroid by developing new methods, therapeutical approaches, vaccines and curing services.
- Swine Model of Haemophilus ducreyi Infection
- Mouse Model of Haemophilus ducreyi Infection
- Macaca Nemestrina Model of Haemophilus ducreyi Infection
We hope that you come into collaboration with us so as to transform the landscape of research and develop the much needed chancroid. Our cutting edge techniques and highly advanced tools allow us to put in a lot of effort and determination into our work, Thus serving the purpose efficiently. If we have been able to capture your attention, feel free to contact us and we will give you an accurate estimate of the service you seek.
References
- Putri, Raja Tina Anggrainy Dwi, et al. "Chancroid Coexisting with Vaginal Candidiasis: A Case Report." Open Access Macedonian Journal of Medical Sciences 9.C (2021): 318-321.
- Fadnavis, Shreya, et al. "Chancroid vaccine: Solving the puzzle within a proteome of Haemophilus ducreyi to reach the target vaccine leads by reverse vaccinology approach." Journal of Pharmacy Research 12.4 (2018): 636.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
